Analyst firms · Raymond James · SPRY
Raymond James SPRY price target and rating history
ARS Pharmaceuticals Inc. (SPRY) · Health Care
Raymond James rates ARS Pharmaceuticals Inc. (SPRY) Outperform with a $17 price target, as of its latest action on Nov 6, 2026. It has published 3 rating actions on SPRY since July 2024, including 1 upgrade and 1 downgrade.
- Current rating
- Outperform
- Price target
- $17
- Median target, all firms
- Too few
- Actions on SPRY
- 3
Raymond James price target on SPRY
Every Raymond James rating on SPRY
- Nov 6, 2026
- Aug 13, 2024
- Jul 25, 2024
How other firms rate SPRY
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Raymond James | Outperform | $17 | Nov 6, 2026 |
| Northland Capital Markets | Outperform | $25 | Apr 9, 2026 |
Questions about Raymond James and SPRY
- What is Raymond James's price target for SPRY?
- Raymond James's latest stated price target for ARS Pharmaceuticals Inc. (SPRY) is $17, from its action on Nov 6, 2026.
- What is Raymond James's rating on SPRY?
- Raymond James rates SPRY Outperform, a bullish rating, as of Nov 6, 2026.
- When did Raymond James last change its view on SPRY?
- On Nov 6, 2026, Raymond James downgrades to Outperform from Strong Buy, price target $17.
All Raymond James ratingsSPRY news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.